Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: A community-based study

Archives of Neurology

Volumn 56, Issue 5, 1999, Pages 595-601

  Aarsland, Dag ^a   Larsen, Jan P ^a   Cummings, Jeffrey L ^b   Laake, Knut ^c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b Univ CA at Los Angeles Sch of Med   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

AGED; ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; DELUSION; DEPRESSION; DISEASE SEVERITY; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS;

AGED; DELUSIONS; EPIDEMIOLOGIC STUDIES; FEMALE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PREVALENCE; PSYCHOTIC DISORDERS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 0032916601     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.5.595     Document Type: Article

References (34)

1. Cummings JL. Behavioral complications of drug treatment in Parkinson's disease. J Am Geriatr Soc. 1991;39:708-716.
2. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson's disease. Arch Neurol. 1996;53:1265-1268.
3. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. In: Weiner WJ, Lang AE, eds. Behavioral Neurology of Movement Disorders: Advances in Neurology. Vol 65. New York, NY: Raven Press; 1995:115-138.
4. Naimark D, Jackson E, Rockwell E, Jeste DV. Psychotic symptoms in Parkinson's disease patients with dementia. J Am Geriatr Soc. 1996;44:296-299.
5. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993;43:2227-2229.
6. Aarsland D, Larsen JP, Cummings JL. Mortality and hallucinations in Parkinson's disease: a four-year longitudinal study. J Neuropsychiatry Clin Neurosci. 1997;9:642.
7. Musser WS, Akil M. Clozapine as a treatment tor psychosis in Parkinson's disease: a review. J Neuropsychiatry Clin Neurosci. 1996;8:1-9.
8. Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA. The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Mov Disord. 1995;10: 541-549.
9. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Lieberman A, eds. Recent Development in Parkinson's Disease. Florham Park, NJ: Macmillan Health Care Information; 1987:153-163.
10. Hoehn MH, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427-442.
11. Larsen JP, Dupont E, Tandberg E. The clinical diagnosis of Parkinson's disease: proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand. 1994;84:242-251.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
13. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the mental state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
14. Gottfries CG, Bråne G, Gullberg B, Steen G. A new rating scale for dementia syndromes. Arch Gerontol Geriatr. 1982;1:311-330.
15. Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson's disease. Arch Neurol. 1996;53:538-542.
16. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
17. Moskovitz C, Moses H III, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry. 1978;135:669-675.
18. Dixon WJ. BMDP Statistical Software Manual. Berkeley: University of California Press; 1992.
19. Wolters EC, Jansen ENH, Tuynman-Qua HG, Bergmans PLM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 1996;47:1085-1087.
20. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry. 1982;39:494-497.
21. Klawans HL. Levodopa-induced psychosis. Psychiatr Ann. 1978;8:447-451.
22. Klein C, Koempf D, Pulkowski U, Moser A, Vieregge P. A study of visual hallucinations in patients with Parkinson's disease. J Neurol. 1997;244:371-377.
23. Larsen JP, Ødegaard H, Tandberg E, Hødnebø A, Aarsland D. Patient characteristics, MRI examination, and dopaminergic drug response in clinical possible Parkinson's disease. J Geriatr Psychiatry Neurol. 1996;9:157-163.
24. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB International Workshop. Neurology. 1996;47:1113-1124.
25. Whitehouse PJ, Hedren JC, White CL III, Price DL. Basal forebrain neurons in dementia of Parkinson's disease. Ann Neurol. 1983;1:243-248.
26. Mach JR, Dysken MW, Kuskowski M, Richelson E, Holden L, Jilk KM. Serum anticholinergic activity in hospitalized older patients with delirium: a preliminary study. J Am Geriatr Soc. 1995;43:491-495.
27. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology. 1996;47:876-883.
28. Perry EK, Kerwin J, Perry RH, Irving D, Blessed G, Fairburn A. Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of the Lewy body type. Dementia. 1990;1:2-4.
29. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1996;61:324-326.
30. Louis ED, Goldman JE, Powers JM, Fahn S. Parkinsonian features of eight pathologically diagnosed cases of diffuse Lewy body disease. Mov Disord. 1995;10: 186-194.
31. Perry RH, Jaros EB, Irving D, et al. What is the neuropathological basis of dementia associated with Lewy bodies? In: Perry RH, McKeith IG, Perry EK, eds. Dementia With Lewy Bodies. Cambridge, England: Cambridge University Press; 1996:212-223.
32. Mega MS, Cummings JL, Fiorello T, Gornbein T. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996;46:130-135.
33. Mayeux R, Stern Y, Cote L, Williams JBW. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology. 1984;34:642-646.
34. Cummings JL. Depression in Parkinson's disease: a review. Am J Psychiatry. 1992;149:443-454.